To continue reading this article, sign up for FREE to
Membership is FREE
and provides you with
instant access
to email newsletters, digital publications, our full content catalogue & more...
Already have an account?
Oxford Biomedica Announces Development Milestone in its Collaboration with Molmed
Read time: Less than a minute
Oxford BioMedica has announced that its partner MolMed has received regulatory approval to start a Phase III trial of TK therapy for high risk acute leukaemia.
Under a license agreement with Oxford BioMedica, MolMed’s TK therapy product employs Oxford BioMedica’s retroviral ex vivo gene delivery technology. The start of a Phase III trial of TK therapy triggers an undisclosed milestone payment to Oxford BioMedica.
Add Technology Networks as a preferred Google source to see more of our trusted coverage.
